Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma
Authors:
Open Access
- 1 August 2014
- journal article
- review article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. 1, 127-135
Abstract
Hepatocellular carcinoma (HCC) is the major leading cause of cancer death worldwide. Hepatitis B virus, hepatitis C virus, alcohol consumption, non-alcoholic fatty liver disease, and diabetes are the major risks for developing HCC. Until now, recurrence and metastasis are the major cause of death in HCC patients. Therefore, identification of new effective molecular targets is an urgent need for treatment of HCC. Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated nuclear receptor which could be activated by PPARγ agonists such as thiazolidinediones, and natural PPARγ ligand (such as 15-deoxy-∆12,14-prostaglandin J2, 15d-PGJ2). Increasing in vitro and in vivo evidence has demonstrated that PPARγ agonists exhibit an inhibitory role on tumor cell growth, migration, and invasion, suggesting that PPARγ activation may play an important role in the regulation of growth of HCC. It has been reported that PPARγ activation by thiazolidinediones or overexpression of PPARγ by virus-mediated gene transfer has shown growth inhibitory effects in hepatoma cells, but the expression level of PPARγ in HCC tissues still remains conflicting. Notably, a novel PPARγ agonist, honokiol, has recently been found to activate the PPARγ /RXR heterodimer, and has also exhibited significant anti-cancer effects in hepatoma cells. In the present review, we summarized studies on the role and the molecular regulation of PPARγ in HCC development in vitro and in vivo. PPARγ has the potential to be a therapeutic target for future treatment of HCC.Keywords
This publication has 86 references indexed in Scilit:
- Honokiol: A non-adipogenic PPARγ agonist from natureBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Homeostatic regulatory role of Pokemon in NF-κB signaling: stimulating both p65 and IκBα expression in human hepatocellular carcinoma cellsMolecular and Cellular Biochemistry, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in miceBritish Journal of Cancer, 2012
- Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitusHepatology, 2011
- Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF ExpressionCell, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancerTrends in Pharmacological Sciences, 2000